 |
|
Experimental Genetics Group
 |
Publications |
|
 |
|
2010 |
|
|
|
|
|
|
|
Serine-409phosphorylationand oxidative damage define aggregation of human protein tau inyeast.
Thomas Vanhelmont, Tom Vandebroek, Ann De Vos, Dick Terwel, Katleen Lemaire, Jayamani
Anandhakumar, Vanessa Franssens, Erwin Swinnen, Fred Van Leuven & Joris Winderickx
FEMS Yeast Res 10 (2010); 992-1005. |
|
|
|
|
|
|
|
Alzheimer's disease: Old problem, new views from transgenic and viral models.
Tomasz Jaworski, Ilse Dewachter, Claire Marie Seymour, Peter Borghgraef, Herman Devijver,
Sebastian Kügler, Fred Van Leuven.
T. Jaworski et al. / Biochimica et Biophysica Acta 1802 (2010) 808–818. |
|
|
|
|
|
|
|
beta-Secretase
cleavage is not required for generation of the intracellular C-terminal
domainof the amyloid precursor family of proteins.
Carlo Sala Frigerio, Julia V. Fadeeva, Aedín M. Minogue, Martin Citron,*, Fred Van Leuven,
Matthias Staufenbiel, Paolo Paganetti, Dennis J. Selkoe and Dominic M. Walsh
Biochim Biophys Acta. 2010 Oct., 1802(10):808-18. Epub 2010 Mar 21. |
|
|
|
|
|
|
|
Pathological Hallmarks,
Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease
of the APP[V717I] London Transgenic Mouse Model.
Jaworski T, Dewachter I, Lechat B, Gees M, Kremer A, Demedts D, Borghgraef P,
Devijver H, Kügler S, Patel S, Woodgett JR, Van Leuven F.
.
International Journal of Alzheimer's DiseaseVolume 2010 (2010); Article ID 417314, 9 pagesdoi:10.4061/2010/417314.
|
|
|
|
|
|
|
|
Upper airway dysfunction of tau-P301L mice correlates
with tauopathy in midbrain and ponto-medullary
brainstem nuclei.
Dutschmann M, Menuet C, Stettner GM, Gestreau C, Borghgraef P, Devijver H, Gielis L, Hilaire G, Van Leuven F.
J Neurosci, 2010, 30(5):1810-1821.
|
|
|
|
|
|
|
|
2009 |
|
|
|
|
|
|
|
AAV-tau mediates
pyramidal neurodegeneration by cell-cycle re-entry without
neurofibrillary tangle formation in wild-type mice.
Jaworski T, Dewachter I, Lechat B, Croes S, Termont A, Demedts D,
Borghgraef P, Devijver H, Filipkowski RK, Kaczmarek L, Kügler S, Van
Leuven F.
PLoS One, 2009, 4(10):e7280. |
|
|
|
|
|
|
|
Absence
of ApoE upregulates murine brain ApoD and ABCA1, but does not effect
brain sterol levels, while human ApoE3 and human ApoE4 upregulate brain
cholesterol precursor levels.
Jansen PJ, Lütjohann D, Thelen KM, von Bergmann K, van Leuven F, Ramaekers FC, Mulder M.
J Alzheimers Dis., 2009 Jul 7, Epub ahead of print. |
ABSTRACT |
|
|
|
|
|
|
Decreased expression of multidrug efflux transporters in the brains of GSK-3beta transgenic mice.
Lim JC, Mickute Z, Zaman M, Hopkins S, Wijesuriya H, Steckler T,
Moechars D, Van Leuven F, Sarnyai Z, Hladky SB, Barrand MA.
Brain Res, 2009 Jun 18, 1276:1-10. |
|
|
|
|
|
|
|
GSK3ß, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at ser-9.
Dewachter I, Ris L, Jaworski T, Seymour CM, Kremer A, Borghgraef P, Devijver H, Godaux E, Van Leuven F.
Neurobiol Dis, 2009 Aug, 35(2):193-200. |
|
|
|
|
|
|
|
11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer’s disease.
Serdons K, Verduyckt T, Vanderghinste D, Borghgraef P, Cleynhens J, Van
Leuven F, Kung H, Bormans G, Verbruggen A.
Eur J Med Chem, 2009 Apr, 44(4):1415-1426. |
|
|
|
|
|
|
|
Synthesis
of 18F-labelled 2-(4’fluorophenyl)/1,3-benzothiazole and evaluation as
amyloid imaging agent in comparison with [11C]PIB.
Serdons
K, Verduyckt T, Vanderghinste D, Cleynhens J, Borghgraef P, Vermaelen
P, Terwinghe C, Van Leuven F, Van Laere K, Kung H, Bormans G,
Verbruggen A.
Bioorg Med Chem Lett, 2009 Feb 1, 19(3):602-605. |
|
|
|
|
|
|
|
Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice.
Dewachter I, Filipkowski RK, Priller C, Ris L, Neyton J, Croes S,
Terwel D, Gysemans M, Devijver H, Borghgraef P, Godaux E, Kaczmarek L,
Herms J, Van Leuven F.
Neurobiol Aging, 2009 Feb, 30(2):241-256. |
|
|
|
|
|
|
|
2008 |
|
|
|
|
|
|
|
Potential amyloid plaque-specific peptides for the diagnosis or Alzheimer’s disease.
Larbanoix L, Burtea C, Laurent S, Van Leuven F, Toubeau G, Vander Elst L, Muller RN.
Neurobiol Aging, 2008 Nov 21. Epub ahaed of print |
|
|
|
|
|
|
|
Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrande cholesterol homeostasis.
Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, St
George-Hyslop P, Sisodia SS, De Strooper B, Heneka MT, Filippov MA,
Müller U, Van Leuven F, Lütjohann D, Walter J.
J Neurosci, 2008 Nov 12, 28(46):12097-12106. |
|
|
|
|
|
|
|
Phosphorylation, lipid raft interaction and traffic of a-synuclein in a yeast model for Parkinson.
Zabrocki P, Bastiaens I, Delay C, Bammens T, Ghillebert R, Pellens K,
De Virgilio C, Van Leuven F, Winderickx J.
Biochim Biophys Acta, 2008 Oct, 1783(10):1767-1780. |
|
|
|
|
|
|
|
Protein folding diseases and neurodegenreation: Lessons learned from yeast.
Winderickx J, Delay C, De Vos A, Klinger H, Pellens K, Vanhelmont T, Van Leuven F, Zabrocki P.
Biochim Biophys Acta, 2008 Jul, 1783(7):1381-1395. |
|
|
|
|
|
|
|
Modulation of synaptic plasticity and Tau phosphorylation by wild-type and mutant presenilin1.
Dewachter I, Ris L, Croes S, Borghgraef P, Devijver H, Voets T, Nilius B, Godaux E, Van Leuven F.
Neurobiol Aging, 2008 May, 29(5):639-652. |
|
|
|
|
|
|
|
Beta-site
amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of
endogenous amyloid beta in wild-type and transgenic mice in vivo.
Hirata-Fukae C, Sadahmed E H, Gooskens T P, Aisen P S, Dewachter I, Devijver H, Van Leuven F, Matsuoka Y.
Neurosci Lett, 2008 Apr 25, 435(3):186-189. |
|
|
|
|
|
|
|
Amyloid activates GSK-3ß to aggravate neuronal tauopathy in bigenic mice.
Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, Van Leuven F.
Am J Pathol, 2008 Mar, 172(3):786-798. |
|
|
|
|
|
|
|
Neurodegeneration
and neuroinflammation in cdk5/p25-inducible mice: a model for
hippocampal sclerosis and neocortical degeneration.
Muyllaert D, Terwel D, Kremer A, Sennvik K, Borghgraef P, Devijver H, Dewachter I, Van Leuven F.
Am J Pathol, 2008 Feb, 172(2):470-485. |
|
|
|
|
|
|
|
Glycogen synthase kinase-3ß, the or a lonk between amyloid and tau pathology?
Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S, Dewachter I, Van Leuven F.
Genes Brains Behav, 2008 Feb, 7 Suppl 1:57-66. |
|
|
|
|
|
|
|
2007 |
|
|
|
|
|
|
|
Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding.
Gevaert T, Vriens J, Segal A, Everaerts W, Roskams T, Talavera K,
Owsianik G, Liedtke W, Daelemans D, Dewachter I, Van Leuven F, Voets T,
De Ridder D, Nilius B.
J Clin Invest, 2007 Nov, 117(11):3453-3462. |
|
|
|
|
|
|
|
Occurrence
and co-localization of amyloid beta-protein and apolipoprotein E in
perivascular drainage channels of wild-type and APP-transgenic mice.
Thal DR, Larionov S, Abramowski D, Wiederhold KH, Van Dooren T,
Yamaguchi H, Haass C, Van Leuven F, Staufenbiel M, Capetillo-Zarate E.
Neurobiol Aging, 2007 Aug, 28(8):1221-1230. |
|
|
|
|
|
|
|
Tau-4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice.
Sennvik K, Boekhoorn K, Lasrado R, Terwel D, Verhaeghe S, Korr H,
Schmitz C, Tomiyama T, Mori H, Krugers H, Joels M, Ramakers GJ,
Lucassen PJ, Van Leuven F.
FASEB J, 2007 Jul, 21(9):2149-2161. |
|
|
|
|
|
|
|
Liposomal
vaccines with conformation-specific amyloid peptide antigens define
immune response and efficacy in APP transgenic mice.
Muhs
A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, van der
Auwera I, Van Leuven F, Sugawara M, Weingertner MC, Bechinger B,
Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A,
Nicolau C.
Proc Natl Acad Sci U S A, 2007 Jun 5, 104(23):9810-9815. |
|
|
|
|
|
|
|
5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice.
Cachard-Chastel M, Lezoualc'h F, Dewachter I, Delomenie C, Croes S,
Devijver H, Langlois M, Van Leuven F, Sicsic S, Gardier AM.
Br J Pharmacol, 2007 Apr, 150(7):883-892. |
|
|
|
|
|
|
|
Mutant presenilin 1 alters synaptic transmission in cultured hippocampal neurons.
Priller C, Dewachter I, Vassallo N, Paluch S, Pace C, Kretzschmar HA, Van Leuven F, Herms J.
J Biol Chem, 2007 Jan 12, 282(2):1119-1127. |
|
|
|
|
|
|
|
2006 |
|
|
|
|
|
|
|
Transgenic Mouse models for Alzheimer’s disease: the role of GSK-3B in combined amyloid and tau-pathology.
Muyllaert D, Terwel D, Borghgraef P, Devijver H, Dewachter I, Van Leuven F.
Rev Neurol, 2006 Oct, 162(10):903-907. |
|
|
|
|
|
|
|
Transgenic mice models for Alzheimer's disease.
Van Leuven F.
Behav Pharmacol, 2006 Sep, 17(5-6):538-539. No abstract available |
|
|
|
|
|
|
|
Microtubule
binding and clustering of human Tau-4R and Tau-P301L proteins isolated
from yeast deficient in orthologues of glycogen synthase kinase-3beta
or cdk5.
Vandebroek T, Terwel D, Vanhelmont T, Gysemans M,
Van Haesendonck C, Engelborghs Y, Winderickx J, Van Leuven F.
J Biol Chem, 2006 Sep 1, 281(35):25388-25397. |
|
|
|
|
|
|
|
Improved
long-term potentiation and memory in young tau-P301L transgenic mice
before onset of hyperphosphorylation and tauopathy.
Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, Ramakers GJ,
de Vos K, Krugers H, Tomiyama T, Mori H, Joels M, Van Leuven F,
Lucassen PJ.
J Neurosci, 2006 Mar 29, 26(13):3514-3523. |
|
|
|
|
|
|
|
A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential.
Griffioen G, Duhamel H, Van Damme N, Pellens K, Zabrocki P, Pannecouque
C, Van Leuven F, Winderickx J, Wera S.
Biochim Biophys Acta, 2006 Mar, 1762(3):312-318. |
|
|
|
|
|
|
|
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter
activity by the activation of PPARgamma.
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P,
Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J,
Klockgether T, Van Leuven F, Heneka MT.
Proc Natl Acad Sci U S A, 2006 Jan 10, 103(2):443-448. |
|
|
|
|
|
|
|
Neuronal
or glial expression of human apolipoprotein e4 affects parenchymal and
vascular amyloid pathology differentially in different brain regions of
double- and triple-transgenic mice.
Van Dooren T,
Muyllaert D, Borghgraef P, Cresens A, Devijver H, Van der Auwera I,
Wera S, Dewachter I, Van Leuven F.
Am J Pathol, 2006 Jan, 168(1):245-260. |
|
|
|
|
|
|
|
2005 |
|
|
|
|
|
|
|
Preparation
of cyclo-phen-type ligands: chelators of metal ions as potential
therapeutic agents in the treatment of neurodegenerative diseases.
Boldron C, Van der Auwera I, Deraeve C, Gornitzka H, Wera S, Pitie M, Van Leuven F, Meunier B.
ChemBioChem, 2005 Nov, 6(11):1976-1980. |
|
|
|
|
|
|
|
A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's
disease.
Van der Auwera I, Wera S, Van Leuven F, Henderson ST.
Nutr Metab (Lond), 2005 Oct 17, 2:28. |
|
|
|
|
|
|
|
Focal
glial activation coincides with increased BACE1 activation and precedes
amyloid plaque deposition in APP[V717I] transgenic mice.
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F.
J Neuroinflammation, 2005 Oct 7, 2:22. |
|
|
|
|
|
|
|
Identification
and isolation of a hyperphosphorylated, conformationally changed
intermediate of human protein tau expressed in yeast.
Vandebroek T, Vanhelmont T, Terwel D, Borghgraef P, Lemaire K,
Snauwaert J, Wera S, Van Leuven F, Winderickx J.
Biochemistry, 2005 Aug 30, 44(34):11466-11475. |
|
|
|
|
|
|
|
Mice lacking Dfna5 show a diverging number of cochlear fourth row outer hair cells.
Van Laer L, Pfister M, Thys S, Vrijens K, Mueller M, Umans L, Serneels
L, Van Nassauw L, Kooy F, Smith RJ, Timmermans JP, Van Leuven F, Van
Camp G.
Neurobiol Dis, 2005 Aug, 19(3):386-399. |
|
|
|
|
|
|
|
Acute
treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces
glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi
C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE.
Brain, 2005 Jun, 128(Pt 6):1442-1453. |
|
|
|
|
|
|
|
Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast.
Zabrocki P, Pellens K, Vanhelmont T, Vandebroek T, Griffioen G, Wera S, Van Leuven F, Winderickx J.
FEBS J, 2005 Mar, 272(6):1386-1400. |
|
|
|
|
|
|
|
Noninvasive
in vivo MRI detection of neuritic plaques associated with iron in
APP[V717I] transgenic mice, a model for Alzheimer's disease.
Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F, Van der Linden A.
Magn Reson Med, 2005 Mar, 53(3):607-613. |
|
|
|
|
|
|
|
Changed
conformation of mutant Tau-P301L underlies the moribund tauopathy,
absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic
mice.
Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F.
J Biol Chem, 2005 Feb 4, 280(5):3963-3973. |
|
|
|
|
|
|
|
Characterization of a murine alpha 2 macroglobulin gene expressed in reproductive and cardiovascular tissue.
He H, McCartney DJ, Wei Q, Esadeg S, Zhang J, Foster RA, Hayes MA, Tayade C, Van Leuven F, Croy BA.
Biol Reprod, 2005 Feb, 72(2):266-275. |
|
|
|
|
|
|
|
Virosome-based
active immunization targets soluble amyloid species rather than plaques
in a transgenic mouse model of Alzheimer's disease.
Zurbriggen R, Amacker M, Kammer AR, Westerfeld N, Borghgraef P, Van Leuven F, Van der Auwera I, Wera S.
J Mol Neurosci, 2005, 27(2):157-166. |
|
|
|
|
|
|
|
Transgenic mouse models for APP processing and Alzheimer's disease: early and late defects.
van Dooren T, Dewachter I, Borghgraef P, Van Leuven F.
Subcell Biochem, 2005, 38:45-63. Review. |
|
|
|
|
|
|
|
Phosphorylation and aggregation of protein tau in humanized yeast cells and in transgenic mouse brain.
Vandebroek T, Terwel D, Vanhelmont T, Winderickx J, Van Leuven F.
New trends in Alzheimer and Parkinson related disorders: ADPD 2005. |
|
|
|
|
|
|
|
Components enhancing alpha-synuclein aggregation and toxicity in a humanized yeast.
Pellens K, Zabrocki P, Vanhelmont T, Vandebroek T, Griffioen G, Wera S, Van Leuven F, Winderickx J.
New trends in Alzheimer and Parkinson related disorders: ADPD 2005. |
|
|
|
|
|
|
|
2004 |
|
|
|
|
|
|
|
Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer's disease and in PS1/APP transgenic mice models.
Boom A, Pochet R, Authelet M, Pradier L, Borghgraef P, Van Leuven F, Heizmann CW, Brion JP.
Biochim Biophys Acta, 2004 Dec 6, 1742(1-3):161-168. |
|
|
|
|
|
|
|
beta-site
amyloid precursor protein cleaving enzyme 1 increases amyloid
deposition in brain parenchyma but reduces cerebrovascular amyloid
angiopathy in aging BACE x APP[V717I] double-transgenic mice.
Willem M, Dewachter I, Smyth N, Van Dooren T, Borghgraef P, Haass C, Van Leuven F.
Am J Pathol, 2004 Nov, 165(5):1621-1631. |
|
|
|
|
|
|
|
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice.
Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I,
Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon
DL.
Proc Natl Acad Sci U S A, 2004 Jul 27, 101(30):11141-11146. |
|
|
|
|
|
|
|
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model.
Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E,
Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux
E, Van Leuven F, Fahrenholz F.
J Clin Invest, 2004 May, 113(10):1456-1464. |
|
|
|
|
|
|
|
2003 |
|
|
|
|
|
|
|
Capacitative calcium entry induces hippocampal long term potentiation in the absence of presenilin-1.
Ris L, Dewachter I, Reverse D, Godaux E, Van Leuven F.
J Biol Chem, 2003 Nov 7, 278(45):44393-44399. |
|
|
|
|
|
|
|
Alpha-2 macroglobulin controls trophoblast positioning in mouse implantation sites.
Esadeg S, He H, Pijnenborg R, Van Leuven F, Croy BA.
Placenta, 2003 Nov, 24(10):912-921. |
|
|
|
|
|
|
|
Nonsteroidal
anti-inflammatory drugs and peroxisome proliferator-activated
receptor-gamma agonists modulate immunostimulated processing of amyloid
precursor protein through regulation of beta-secretase.
Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, Van Leuven F, Heneka MT.
J Neurosci, 2003 Oct 29, 23(30):9796-9804. |
|
|
|
|
|
|
|
Influence of exonic polymorphisms in the gene for LDL receptor-related protein (LRP) on risk of coronary artery disease.
Pocathikorn A, Granath B, Thiry E, Van Leuven F, Taylor R, Mamotte C.
Atherosclerosis, 2003 May, 168(1):115-121. |
|
|
|
|
|
|
|
Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.
Frenkel D, Dewachter I, Van Leuven F, Solomon B.
Vaccine, 2003 Mar 7, 21(11-12):1060-1065. |
|
|
|
|
|
|
|
Evaluation of 18F-FA-4 and 11C-pipzA-4 as radioligands for the in vivo evaluation of the high-affinity choline uptake system.
Gilissen C, de Groot TJ, Bronfman F, Van Leuven F, Verbruggen AM, Bormans GM.
J Nucl Med, 2003 Feb, 44(2):269-275. |
|
|
|
|
|
|
|
Capacitive
calcium entry is directly attenuated by mutant presenilin-1,
independent of the expression of the amyloid precursor protein.
Herms J, Schneider I, Dewachter I, Caluwaerts N, Kretzschmar H, Van Leuven F.
J Biol Chem, 2003 Jan 24, 278(4):2484-2489. |
|
|
|
|
|
|
|
Neuropathobiology in transgenic mice. The case of Alzheimer's disease. .
Van Dorpe J, Spittaels K, Van den Haute CV, Dewachter I, Moechars D, Geerts H, Van Leuven F.
Methods Mol Biol, 2003, 209:333-361. Review. |
|
|
|
|
|
|
|
2002 |
|
|
|
|
|
|
Unusual association of Hodgkin's disease and sarcoidosis.
Simsek S, Van Leuven F, Bronsveld W, Ooms GH, Groeneveld AB, de Graaff CS.
Neth J Med, 2002 Dec, 60(11):438-440. |
|
|
|
|
|
|
|
Secretases as targets for the treatment of Alzheimer's disease: the prospects.
Dewachter I, Van Leuven F.
Lancet Neurol, 2002 Nov, 1(7):409-416. Review. |
|
|
|
|
|
|
|
Increased
Trypanosoma cruzi invasion and heart fibrosis associated with high
transforming growth factor beta levels in mice deficient in
alpha(2)-macroglobulin.
Waghabi MC, Coutinho CM, Soeiro
MN, Pereira MC, Feige JJ, Keramidas M, Cosson A, Minoprio P, Van Leuven
F, Araujo-Jorge TC.
Infect Immun, 2002 Sep, 70(9):5115-5123. |
|
|
|
|
|
|
|
Unhampered prion neuroinvasion despite impaired fast axonal transport in transgenic mice overexpressing four-repeat tau.
Kunzi V, Glatzel M, Nakano MY, Greber UF, Van Leuven F, Aguzzi A.
J Neurosci, 2002 Sep 1, 22(17):7471-7477. |
|
|
|
|
|
|
|
Functional expression of murine LRP1 requires correction of Lrp1 cDNA sequences.
Smeijers L, Willems S, Lauwers A, Thiry E, Van Leuven F, Roebroek AJ.
Biochim Biophys Acta, 2002 Aug 19, 1577(1):155-158. |
|
|
|
|
|
|
|
Role of alpha(2)-macroglobulin in fever and cytokine responses induced by lipopolysaccharide in mice.
Gourine AV, Gourine VN, Tesfaigzi Y, Caluwaerts N, Van Leuven F, Kluger MJ.
Am J Physiol Regul Integr Comp Physiol, 2002 Jul, 283(1):R218-226. |
|
|
|
|
|
|
|
Reduction
of amyloid load and cerebral damage in a transgenic mouse model of
Alzheimer's disease by treatment with a beta-sheet breaker peptide.
Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J,
Dewachter I, Banks WA, Van Leuven F, Soto C.
FASEB J, 2002 Jun, 16(8):860-862. |
|
|
|
|
|
|
|
Proteomics analysis of the neurodegeneration in the brain of tau transgenic
Tilleman K, Van den Haute C, Geerts H, Van Leuven F, Esmans EL, Moens L.
Proteomics, 2002 Jun, 2(6):656-665. |
|
|
|
|
|
|
|
Neuronal
deficiency of presenilin 1 inhibits amyloid plaque formation and
corrects hippocampal long-term potentiation but not a cognitive defect
of amyloid precursor protein [V717I] transgenic mice.
Dewachter I, Reverse D, Caluwaerts N, Ris L, Kuiperi C, Van den Haute
C, Spittaels K, Umans L, Serneels L, Thiry E, Moechars D, Mercken M,
Godaux E, Van Leuven F.
J Neurosci, 2002 May 1, 22(9):3445-3453. |
|
|
|
|
|
|
|
Translocation of the HMGI-C ( HMGA2) gene in a benign mesenchymoma (chondrolipoangioma).
Van Dorpe J, Dal Cin P, Weremowicz S, Van Leuven F, de Wever I, Van den Berghe H, Fletcher CD, Sciot R.
Virchows Arch, 2002 May, 440(5):485-490. |
|
|
|
|
|
|
|
Coexpression
of GSK-3beta corrects phenotypic aberrations of dorsal root ganglion
cells, cultured from adult transgenic mice overexpressing human protein
tau.
Nuydens R, Van Den Kieboom G, Nolten C, Verhulst C,
Van Osta P, Spittaels K, Van den Haute C, De Feyter E, Geerts H, Van
Leuven F.
Neurobiol Dis, 2002 Feb, 9(1):38-48. |
|
|
|
|
|
|
|
Mice
lacking alpha(2)-macroglobulin show an increased host defense against
Gram-negative bacterial sepsis, but are more susceptible to endotoxic
shock.
Hochepied T, Van Leuven F, Libert C.
Eur Cytokine Netw, 2002 Jan-Mar, 13(1):86-91. |
|
|
|
|
|
|
|
Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.
Terwel D, Dewachter I, Van Leuven F.
Neuromolecular Med, 2002, 2(2):151-165. Review. |
|
|
|
|
|
|
|
Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice.
Spittaels K, Van den Haute C, Van Dorpe J, Terwel D, Vandezande K,
Lasrado R, Bruynseels K, Irizarry M, Verhoye M, Van Lint J, Vandenheede
JR, Ashton D, Mercken M, Loos R, Hyman B, Van der Linden A, Geerts H,
Van Leuven F.
Neuroscience, 2002, 113(4):797-808. |
|
|
|
|
|
|
|
Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view.
Tilleman K, Stevens I, Spittaels K, Haute CV, Clerens S, Van Den Bergh
G, Geerts H, Van Leuven F, Vandesande F, Moens L.
Proteomics, 2002 Jan, 2(1):94-104. |
|
|
|
|
|
|
|
2001 |
|
|
|
|
|
|
|
Impact of genetic defects on atherosclerosis in patients suspected of familial hypercholesterolaemia.
Descamps OS, Gilbeau JP, Leysen X, Van Leuven F, Heller FR.
Eur J Clin Invest, 2001 Nov, 31(11):958-965. |
|
|
|
|
|
|
|
The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia.
Descamps OS, Leysen X, Van Leuven F, Heller FR.
Atherosclerosis, 2001 Aug, 157(2):514-518. |
|
|
|
|
|
|
|
Differential
expression of mRNA coding for the alpha-2-macroglobulin family and the
LRP receptor system in C57BL/6J and C3H/HeJ male mice.
Correia Soeiro MN, Paiva MM, Waghabi M, Meirelles MN, Lorent K, Araujo-Jorge TC, Van Leuven F.
Cell Struct Funct, 2001 Jun, 26(3):161-167. |
|
|
|
|
|
|
|
Mutant
presenilins disturb neuronal calcium homeostasis in the brain of
transgenic mice, decreasing the threshold for excitotoxicity and
facilitating long-term potentiation.
Schneider I, Reverse
D, Dewachter I, Ris L, Caluwaerts N, Kuiperi C, Gilis M, Geerts H,
Kretzschmar H, Godaux E, Moechars D, Van Leuven F, Herms J.
J Biol Chem, 2001 Apr 13, 276(15):11539-11544. |
|
|
|
|
|
|
|
Sequencing of the coding exons of the LRP1 and LDLR genes on individual DNA samples reveals novel mutations in both genes.
Van Leuven F, Thiry E, Lambrechts M, Stas L, Boon T, Bruynseels K, Muls E, Descamps O.
Atherosclerosis, 2001 Feb 15, 154(3):567-577. |
|
|
|
|
|
|
|
Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice.
Van den Haute C, Spittaels K, Van Dorpe J, Lasrado R, Vandezande K, Laenen I, Geerts H, Van Leuven F.
Biochem Soc Symp. 2001;(67):203-10. |
|
|
|
|
|
|
|
Modelling Alzheimer's disease in multiple transgenic mice.
Dewachter I, Moechars D, van Dorpe J, Tesseur I, Van den Haute C, Spittaels K, Van Leuven F.
Biochem Soc Symp, 2001, 8(1):32-44. |
|
|
|
|
|
|
|
Phosphorylation of protein tau and rescue of protein tau-induced axonopathy by GSK-3ß in GSK-3ßhtau40 double transgenic mice.
Spittaels K, Van Den Haute C, Van Dorpe J, Van Leuven F.
Alzheimer's disease: Advances in Etiology, Pathogenesis and Therapeutics, 2001, 609-620. |
|
|
|
|
|
|
|
2000 |
|
|
|
|
|
|
|
Glycogen
synthase kinase-3beta phosphorylates protein tau and rescues the
axonopathy in the central nervous system of human four-repeat tau
transgenic mice.
Spittaels K, Van den Haute C, Van Dorpe
J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen
I, Boon T, Van Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F.
J Biol Chem, 2000 Dec 29, 275(52):41340-41349. |
|
|
|
|
|
|
|
Modeling
Alzheimer's disease in transgenic mice: effect of age and of
presenilin1 on amyloid biochemistry and pathology in APP/London mice.
Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F.
Exp Geront, 2000 Sep, 35(6-7):831-841. Review. |
|
|
|
|
|
|
|
Single and multiple transgenic mice as models for Alzheimer's disease.
Van Leuven F.
Prog Neurobiol, 2000 Jun, 61(3):305-312. Review. |
|
|
|
|
|
|
|
Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons.
Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den
Haute C, Mercken M, Moechars D, Laenen I, Kuiperi C, Bruynseels K,
Tesseur I, Loos R, Vanderstichele H, Checler F, Sciot R, Van Leuven F.
Am J Pathol, 2000 Oct, 157(4):1283-1298. |
|
|
|
|
|
|
|
Aging
increased amyloid peptide and caused amyloid plaques in brain of old
APP/V717I transgenic mice by a different mechanism than mutant
presenilin1.
Dewachter I, Van Dorpe J, Smeijers L, Gilis
M, Kuiperi C, Laenen I, Caluwaerts N, Moechars D, Checler F,
Vanderstichele H, Van Leuven F.
J Neurosci, 2000 Sep 1, 20(17):6452-6458. |
|
|
|
|
|
|
|
Acetylcholinesterase-positive
fiber deafferentation and cell shrinkage in the septohippocampal
pathway of aged amyloid precursor protein london mutant transgenic mice.
Bronfman FC, Moechars D, Van Leuven F.
Neurobiol Dis, 2000 Jun, 7(3):152-168. |
|
|
|
|
|
|
|
Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice.
Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F.
Am J Pathol, 2000 Mar, 156(3):951-964. |
|
|
|
|
|
|
|
Behavioral
disturbances without amyloid deposits in mice overexpressing human
amyloid precursor protein with Flemish (A692G) or Dutch (E693Q)
mutation.
Kumar-Singh S, Dewachter I, Moechars D, Lubke U,
De Jonghe C, Ceuterick C, Checler F, Naidu A, Cordell B, Cras P, Van
Broeckhoven C, Van Leuven F.
Neurobiol Dis, 2000 Feb, 7(1):9-22. |
|
|
|
|
|
|
|
Prominent
axonopathy and disruption of axonal transport in transgenic mice
expressing human apolipoprotein E4 in neurons of brain and spinal cord.
Tesseur I, Van Dorpe J, Bruynseels K, Bronfman F, Sciot R, Van Lommel A, Van Leuven F.
Am J Pathol, 2000 Nov, 157(5):1495-1510. |
|
|
|
|
|
|
|
No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice.
Bronfman FC, Tesseur I, Hofker MH, Havekens LM, Van Leuven F.
Neuroscience, 2000, 97(3):411-418. |
|
|
|
|
|
|
|
1999 |
|
|
|
|
|
|
|
Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein.
Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K,
Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van
Leuven F.
Am J Pathol, 1999 Dec, 155(6):2153-2165. |
|
|
|
|
|
|
|
alpha2-macroglobulin- and murinoglobulin-1- deficient mice. A mouse model for acute pancreatitis.
Umans L, Serneels L, Overbergh L, Stas L, Van Leuven F.
Am J Pathol, 1999 Sep, 155(3):983-993. |
|
|
|
|
|
|
|
Lipoprotein
receptor-related protein in brain and in cultured neurons of mice
deficient in receptor-associated protein and transgenic for
apolipoprotein E4 or amyloid precursor protein.
Umans L, Serneels L, Lorent K, Dewachter I, Tesseur I, Moechars D, Van Leuven F.
Neuroscience, 1999, 94(1):315-321. |
|
|
|
|
|
|
|
Premature
death in transgenic mice that overexpress a mutant amyloid precursor
protein is preceded by severe neurodegeneration and apoptosis.
Moechars D, Lorent K, Van Leuven F.
Neuroscience, 1999, 91(3):819-830. |
|
|
|
|
|
|
|
Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain.
Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A,
Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van
Leuven F.
J Biol Chem, 1999 Mar 5, 274(10):6483-6492. |
|
|
|
|
|
|
|
Celbiologische studie van de ziekte van Alzheimer.
Annaert W, Van Leuven F, De Strooper B.
Tijdschrift voor Geneeskunde, 1999, 55 nr.1 |
|
|
|
|
|
|
|
Transgene muizen als model voor de ziekte van Alzheimer.
Moechars D, Van Leuven F.
Tijdschrift voor Geneeskunde, 1999, 55 nr.3 |
|
|
|
|
|
|
|
1998 |
|
|
|
|
|
|
|
Representational difference analysis using minute quantities of DNA.
Michiels L, Van Leuven F, van den Oord JJ, De Wolf-Peeters C, Delabie J.
Nucleic Acids Res, 1998 Aug 1, 26(15):3608-3610. |
NA
|
|
|
|
|
|
|
Transgenic mice, derived neurons and organotypic cultures as model systems to study Alzheimer's Disease.
Moechars D, De Strooper B, Dewachter I, Van Leuven F.
MFLRBER, 1998, 63(4a):1099-1105. |
NA
|
|
|
|
|
|
|
Strategy
to sequence the 89 exons of the human LRP1 gene coding for the
lipoprotein receptor related protein: identification of one expressed
mutation among 48 polymorphisms.
Van Leuven F, Stas L, Thiry E, Nelissen B, Miyake Y.
Genomics, 1998 Sep 1, 52(2):138-144. |
|
|
|
|
|
|
|
Analysis
of the human LRPAP1 gene coding for the lipoprotein receptor-associated
protein: identification of 22 polymorphisms and one mutation.
Van Leuven F, Thiry E, Stas L, Nelissen B.
Genomics, 1998 Sep 1, 52(2):145-151. |
|
|
|
|
|
|
|
Transgenic
mice expressing an alpha-secretion mutant of the amyloid precursor
protein in the brain develop a progressive CNS disorder.
Moechars D, Lorent K, Dewachter I, Baekelandt V, De Strooper B, Van Leuven F.
Behav Brain Res, 1998 Sep, 95(1):55-64. |
|
|
|
|
|
|
|
Molecular
cloning of a gene on chromosome 19q12 coding for a novel intracellular
protein: analysis of expression in human and mouse tissues and in human
tumor cells, particularly Reed-Sternberg cells in Hodgkin disease.
Van Leuven F, Torrekens S, Moechars D, Hilliker C, Buellens M, Bollen M, Delabie J.
Genomics, 1998 Dec 15, 54(3):511-520. |
|
|
|
|
|
|
|
Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs.
Moechars D, Gilis M, Kuiperi C, Laenen I, Van Leuven F.
Neuroreport, 1998 Nov 16, 9(16):3561-3564. |
|
|
|
|
|
|
|
Transgenic mouse models for Alzheimer's Disease.
Moechars D, Lorent K, Dewachter I, Van Leuven F.
NNovel systems for the study of human disease, OECD PROCEEDINGS,, 1998, p.283-297. |
NA
|
|
|
|
|
|
|
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor
protein.
De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert
W, Von Figura K, Van Leuven F.
Nature, 1998 Jan 22, 319(6665):387-390. |
|
|
|
|
|
|
|
1997 |
|
|
|
|
|
|
|
Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins.
De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K,
Cordell B, Moechars D, Bollen M, Fraser P, George-Hyslop PS, Van Leuven
F.
J Biol Chem, 1997 Feb 7, 272(6):3590-3598. |
|
|
|
|
|
|
|
Alpha-2-macroglobulin binds to the surface of Trypanosoma cruzi.
Coutinho CM, Cavalcanti GH, Van Leuven F, Araujo-Jorge TC.
Parasitol, 1997 , 83(2):144-150. |
|
|
|
|
|
|
|
1996 |
|
|
|
|
|
|
|
Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D.
Saftig P, Peters C, von Figura K, Craessaerts K, Van Leuven F, De Strooper B.
J Biol Chem, 1996 Nov 1, 271(44):27241-27244. |
|
|
|
|
|
|
|
Murine
alpha-macroglobulins demonstrate divergent activities as neutralizers
of transforming growth factor-beta and as inducers of nitric oxide
synthesis. A possible mechanism for the endotoxin insensitivity of the
alpha2-macroglobulin gene knock-out mouse.
Webb DJ, Wen J, Lysiak JJ, Umans L, Van Leuven F, Gonias SL.
J Biol Chem, 1996 Oct 4, 271(40):24982-24988. |
|
|
|
|
|
|
|
The beta-amyloid domain is essential for axonal sorting of amyloid precursor protein.
Tienari PJ, De Strooper B, Ikonen E, Simons M, Weidemann A, Czech C,
Hartmann T, Ida N, Multhaup G, Masters CL, Van Leuven F, Beyreuther K,
Dotti CG.
EMBO J, 1996 Oct 1, 15(19):5218-5229. |
|
|
|
|
|
|
|
Expression
in brain of amyloid precursor protein mutated in the alpha-secretase
site causes disturbed behavior, neuronal degeneration and premature
death in transgenic mice.
Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leuven F.
EMBO J, 1996 Mar 15, 15(6):1265-1274. |
|
|
|
|
|
|
|
A
68-kD antigen, which is probably an N-terminal fragment of the VLA-5
alpha 5-subunit, is specific for differentiating keratinocytes.
De Strooper B, Wu RR, Jaspers M, Van der Schueren B, Vekemans S,
Carmeliet G, Van Leuven F, Van Den Oord J, Cassiman JJ.
Dermatology, 1996 , 193(3):212-220. |
|
|
|
|
|
|
|
Molecular
cloning and characterization of the human interleukin-11 receptor
alpha-chain gene, IL11RA, located on chromosome 9p13.
Van Leuven F, Stas L, Hilliker C, Miyake Y, Bilinski P, Gossler A.
Genomics, 1996 Jan 1, 31(1):65-70. |
|
|
|
|
|
|
|
1995 |
|
|
|
|
|
|
|
Exchanging
the extracellular domain of amyloid precursor protein for horseradish
peroxidase does not interfere with alpha-secretase cleavage of the
beta-amyloid region, but randomizes secretion in Madin-Darby canine
kidney cells.
De Strooper B, Craessaerts K, Van Leuven F, Van Den Berghe H.
J Biol Chem, 1995 Dec 22, 270(51):30310-30314. |
|
|
|
|
|
|
|
Production
of intracellular amyloid-containing fragments in hippocampal neurons
expressing human amyloid precursor protein and protection against
amyloidogenesis by subtle amino acid substitutions in the rodent
sequence.
De Strooper B, Simons M, Multhaup G, Van Leuven F, Beyreuther K, Dotti CG.
EMBO J, 1995 Oct 16, 14(20):4932-4938. |
|
|
|
|
|
|
|
Targeted inactivation of the mouse alpha 2-macroglobulin gene.
Umans L, Serneels L, Overbergh L, Lorent K, Van Leuven F, Van den Berghe H.
J Biol Chem, 1995 Aug 25, 270(34):19778-19785. |
|
|
|
|
|
|
|
Expression
of mouse alpha-macroglobulins, lipoprotein receptor-related protein,
LDL receptor, apolipoprotein E, and lipoprotein lipase in pregnancy.
Overbergh L, Lorent K, Torrekens S, Van Leuven F, Van den Berghe H.
J Lipid Res, 1995 Aug, 36(8):1774-1786. |
|
|
|
|
|
|
|
Expression in mouse embryos and in adult mouse brain of three members
of the amyloid precursor protein family, of the alpha-2-macroglobulin
receptor/low density lipoprotein receptor-related protein and of its
ligands apolipoprotein E, lipoprotein lipase, alpha-2-macroglobulin and
the 40,000 molecular weight receptor-associated protein.
Lorent K, Overbergh L, Moechars D, De Strooper B, Van Leuven F, Van den Berghe H.
Neuroscience, 1995 Apr, 65(4):1009-1025. |
|
|
|
|
|
|
|
Amyloid precursor protein accumulation in Lewy body dementia and Alzheimer's disease.
Van Gool D, De Strooper B, Van Leuven F, Dom R.
Dementia, 1995 Mar-Apr, 6(2):63-68. |
|
|
|
|
|
|
|
Basolateral
secretion of amyloid precursor protein in Madin-Darby canine kidney
cells is disturbed by alterations of intracellular pH and by
introducing a mutation associated with familial Alzheimer's disease.
De Strooper B, Craessaerts K, Dewachter I, Moechars D, Greenberg B, Van Leuven F, Van den Berghe H.
J Biol Chem, 1995 Feb 24, 270(8):4058-4065. |
|
|
|
|
|
|
|
Cloning,
characterization, and chromosomal localization to 4p16 of the human
gene (LRPAP1) coding for the alpha 2-macroglobulin receptor-associated
protein and structural comparison with the murine gene coding for the
44-kDa heparin-binding protein.
Van Leuven F, Hilliker C, Serneels L, Umans L, Overbergh L, De Strooper B, Fryns JP, Van den Berghe H.
Genomics, 1995 Jan 20, 25(2):492-500. |
|
|
|
|
|
|
|
Amyloid
precursor protein is not processed by furin, PACE 4, PC1/3, PC2, PC4
and PC5/6 of the furin family of proprotein processing enzymes.
De Strooper B, Creemers JW, Moechars D, Huylebroeck D, Van De Ven WJ, Van Leuven F, Van den Berghe H.
Biochim Biophys Acta, 1995 Jan 19, 1246(2):185-188. |
|
|
|
|
|
|
|
1994 |
|
|
|
|
|
|
|
Structure of the gene (LRP1) coding for the human alpha 2-macroglobulin receptor lipoprotein receptor-related protein.
Van Leuven F, Stas L, Hilliker C, Lorent K, Umans L, Serneels L,
Overbergh L, Torrekens S, Moechars D, De Strooper B, et al.
Genomics, 1994 Nov 1, 24(1):78-89. |
|
|
|
|
|
|
|
Genomic cloning of the mouse LDL receptor related protein/alpha 2-macroglobulin receptor gene.
van der Zee A, Stas L, Hilleker C, Van Leuven F, van Dijk KW, Havekes L, Frants R, Hofker M.
Genomics, 1994 Sep 1, 23(1):256-259. |
|
|
|
|
|
|
|
Identification
of four genes coding for isoforms of murinoglobulin, the monomeric
mouse alpha 2-macroglobulin: characterization of the exons coding for
the bait region.
Overbergh L, Hilliker C, Lorent K, Van Leuven F, Van den Berghe H.
Genomics, 1994 Aug 1, 22(3):530-539. |
|
|
|
|
|
|
|
Molecular cloning of the mouse gene coding for alpha 2-macroglobulin and targeting of the gene in embryonic stem cells.
Umans L, Serneels L, Hilliker C, Stas L, Overbergh L, De Strooper B, Van Leuven F, Van den Berghe H.
Genomics, 1994 Aug, 22(3):519-529. |
|
|
|
|
|
|
|
Distribution
of mRNA coding for alpha-2-macroglobulin, the murinoglobulins, the
alpha-2-macroglobulin receptor and the alpha-2-macroglobulin receptor
associated protein during mouse embryogenesis and in adult tissues.
Lorent K, Overbergh L, Delabie J, Van Leuven F, Van den Berghe H.
Differentiation, 1994 Feb;55(3):213-23. |
|
|
|
|
|
|
|
Localization
of the gene (RSN) coding for restin, a marker for Reed-Sternberg cells
in Hodgkin's disease, to human chromosome band 12q24.3 and YAC cloning
of the locus.
Hilliker C, Delabie J, Speleman F, Bilbe G, Bruggen J, Van Leuven F, Van den Berghe H.
Cytogenet Cell Genet, 1994;65(3):172-6. |
|
|
|
|
|
|
|
1993 |
|
|
|
|
|
|
|
alpha 2-Macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease.
Van Gool D, De Strooper B, Van Leuven F, Triau E, Dom R.
Neurobiol Aging, 1993 May-Jun;14(3):233-7. |
|
|
|
|
|
|
|
Molecular cloning and sequencing of the murine alpha-2-macroglobulin receptor cDNA.
Van Leuven F, Stas L, Raymakers L, Overbergh L, De Strooper B, Hilliker
C, Lorent K, Fias E, Umans L, Torrekens S, et al.
Biochim Biophys Acta, 1993 Apr 29;1173(1):71-4. |
|
|
|
|
|
|
|
Study
of the synthesis and secretion of normal and artificial mutants of
murine amyloid precursor protein (APP): cleavage of APP occurs in a
late compartment of the default secretion pathway.
De Strooper B, Umans L, Van Leuven F, Van Den Berghe H.
J Cell Biol, 1993 Apr;121(2):295-304. |
|
|
|
|
|
|
|
Mannose-specific lectins bind alpha-2-macroglobulin and an unknown protein from human plasma.
Van Leuven F, Torrekens S, Van Damme E, Peumans W, Van den Berghe H.
Protein Sci, 1993 Feb;2(2):255-63. |
|
|
|
|
|
|
|
1992 |
|
|
|
|
|
|
|
Expression of the novel intermediate filament-associated protein restin in Hodgkin's disease and anaplastic large-cell lymphoma.
Delabie J, Shipman R, Bruggen J, De Strooper B, Van Leuven F, Tarcsay
L, Cerletti N, Odink K, Diehl V, Bilbe G, et al.
Blood, 1992 Dec 1;80(11):2891-6. |
|
|
|
|
|
|
|
The
primary sequence and the subunit structure of mouse
alpha-2-macroglobulin, deduced from protein sequencing of the isolated
subunits and from molecular cloning of the cDNA.
Van Leuven F, Torrekens S, Overbergh L, Lorent K, de Strooper B, van den Berghe H.
Eur J Biochem, 1992 Nov 15;210(1):319-27. |
|
|
|
|
|
|
|
Alpha
2-macroglobulin and other proteinase inhibitors do not interfere with
secretion of amyloid precursor protein in mouse neuroblastoma cells.
De Strooper B, Van Leuven F, Van den Berghe H.
FEBS Lett, 1992 Aug 10;308(1):50-3. |
|
|
|
|
|
|
|
Ultrastructure of alpha 2-macroglobulins.
Delain E, Pochon F, Barray M, Van Leuven F.
Electron Microsc Rev, 1992;5(2):231-81. |
|
|
|
|
|
|
|
1991 |
|
|
|
|
|
|
|
The
amyloid beta protein precursor or proteinase nexin II from mouse is
closer related to its human homolog than previously reported.
De Strooper B, Van Leuven F, Van den Berghe H.
Biochim Biophys Acta, 1991 Dec 2;1129(1):141-3. |
|
|
|
|
|
|
|
Molecular characterization of the murinoglobulins.
Overbergh L, Torrekens S, Van Leuven F, Van den Berghe H.
J Biol Chem, 1991 Sep 5;266(25):16903-10. |
|
|
|
|
|
|
|
Alpha 2 macroglobin in acute pancreatitis. Raised values of alpha 2 macroglobulin-protease complexes in severe and mild attacks.
Banks RE, Evans SW, Alexander D, Van Leuven F, Whicher JT, McMahon MJ.
Gut, 1991 Apr;32(4):430-4. |
|
|
|
|
